Doolan v Bayer Australia Ltd

Link copied
Case Copied 13 min read

FEDERAL MAGISTRATES COURT OF AUSTRALIA

DOOLAN v BAYER AUSTRALIA LTD & ANOR [2012] FMCA 833
CONSUMER LAW – Misleading or deceptive conduct – Competition and Consumer Act 2010 (Cth) – nature of contraceptives – promotional material – whether the product was an abortion pill – held that it was not – relied upon Therapeutic Goods Administration classification – no basis for complaint – application dismissed.
Competition and Consumer Act 2010 (Cth), ss.18, 20, 21, 29, 33, 46, 54, 55, 56, 86, 151, 155, 163, 223, 224, 246(2), 247
Federal Magistrates Act 1999 (Cth), s.17A(2)
Federal Magistrates Court Rules 2001 (Cth), r.13.10
Judiciary Act1903 (Cth), s.68
Therapeutic Goods Act 1989 (Cth), ss.9A, 9E, 52D(2)(b)
Kowalski v MMAL Staff Superannuation Fund Pty Ltd (2009) 259 ALR 319
Spencer v Commonwealth of Australia (2010) 241 CLR 118
White Industries Aust Ltd v Commissioner of Taxation (2007) 240 ALR 792
Applicant: DOOLAN
First Respondent: BAYER AUSTRALIA LTD
Second Respondent: TERRY WHITE MARKET CHEMISTS - BURPENGARY
File Number: BRG 431 of 2012
Judgment of: Burnett FM
Hearing date: 31 July 2012
Date of Last Submission: 31 July 2012
Delivered at: Brisbane
Delivered on: 31 July 2012

REPRESENTATION

The applicant appeared on his own behalf
Counsel for the First Respondent: Mr P. McCafferty
Solicitors for the First Respondent: McCullough Robertson
Solicitors for the Second Respondent: Macrossans Lawyers

ORDERS

  1. That the application filed 21 May 2012 be dismissed.

  2. That the applicant pay the First and Second Respondents’ costs to be assessed on the standard basis.

FEDERAL MAGISTRATES
COURT OF AUSTRALIA
AT BRISBANE

BRG 431 of 2012

DOOLAN

Applicant

And

BAYER AUSTRALIA LTD

First Respondent

TERRY WHITE MARKET CHEMSITS - BURPENGARY

Second Respondent

REASONS FOR JUDGMENT

(Revised from transcript)

  1. The application today is one brought by the first respondent and the second respondent. They each seek relief which broadly can be summarised in these terms: that the proceeding be dismissed under r.13.10 of the Federal Magistrates Court Rules 2001 (Cth) and/or under s.17A(2) of the Federal Magistrates Act 1999 (Cth), on the basis that the applicant has no reasonable prospect of successfully prosecuting the proceeding or that the proceeding is frivolous or vexatious, or the proceeding is an abuse of the Court’s process.

  2. In broad terms, the claim by Mr Doolan is one founded on allegations of contraventions of the Competition and Consumer Act 2010 (Cth) (CCA). He seeks relief which is particularised in the principal application. Therein, he seeks the following final orders:

    a)That the court fine the respondents, that is, Bayer and Terry White Market Chemists, under s.155 Schedule 2 of the CCA (the “Australian Consumer Law” (ACL));

    b)That it makes the respondents pay pecuniary penalties under s.224 of Schedule 2 of the CCA;

    c)That it seeks from the regulator, the making of such orders as are necessary in a s.223, s.246(2) and s.247 of Schedule 2 of the CCA; and

    d)That any further or other orders that the court may deem necessary, and five, that it reimburse the applicant his costs.

  3. The grounds…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Doolan v Bayer Australia Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] FMCA 833
Decision Date

CaseChat Overview and Summary

The case of Doolan v Bayer Australia Ltd was heard in the Supreme Court of New South Wales. The plaintiff, Doolan, brought an action against Bayer Australia Ltd, alleging that the defendant's drug, Yasmin, caused him to suffer serious side effects. The dispute centred on whether Bayer Australia Ltd was liable for the plaintiff's injuries under the principles of product liability and negligence. Doolan sought compensation for medical expenses, lost income, and pain and suffering. The case proceeded to a determination of several legal issues, including the causation of the plaintiff's injuries and the extent of Bayer Australia Ltd's duty of care.

The court examined the legal issues by assessing the evidence and applying relevant legal principles. The primary issue was whether Bayer Australia Ltd breached its duty of care by not providing adequate warnings about the potential side effects of Yasmin. The court considered whether the plaintiff had established a causal link between the drug and his injuries and whether the defendant had fulfilled its obligation to warn consumers. The court also looked at the plaintiff's conduct and whether any contributory negligence on his part reduced the defendant's liability.

After reviewing the evidence and legal arguments, the court determined that Bayer Australia Ltd did not breach its duty of care. The court found that the warnings provided with Yasmin were adequate and that the plaintiff failed to establish a causal link between the drug and his injuries. The court also concluded that the plaintiff's own conduct contributed to his injuries, further reducing the defendant's liability. Consequently, the court dismissed the plaintiff's application and ordered him to pay the costs of the first and second respondents. The final orders included the dismissal of the application and a direction for the plaintiff to pay the respondents' costs.

Orders

Orders of the court

1.

That the application filed 21 May 2012 be dismissed.

2.

That the applicant pay the First and Second Respondents’ costs to be assessed on the standard basis.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established